Raymond James downgrades Masimo stock rating on Danaher deal By Investing.com

Raymond James downgraded Masimo to Market Perform from Outperform, expecting Danaher’s acquisition to close in Q2–Q3 2026 with no competing bids and noting shares trade near the $180 offer price. The purchase implies a 17.5x EBITDA multiple and values Masimo at 5.7x Raymond James’ 2027 revenue estimate. Masimo reported preliminary 2025 revenue of ~$1.52B (+9% YoY) and anticipates Q4 revenue of ~$411M (+12% reported, +11% constant currency). Separately, Clairity received FDA De Novo authorization for an AI breast cancer risk platform and appointed Connie Lehman as CEO, with Joe Kiani named Clairity board chairman.

Analysis

Market pricing has effectively baked in deal certainty, which compresses immediate upside for MASI equity and shifts the primary return vector to merger-arbitrage carry versus binary event risk. That binary — litigation, regulatory hiccup, or a competing bid — is low-probability but high-payoff, meaning asymmetric position sizing is critical: small positions can harvest carry while preserving capital for tail outcomes. Danaher’s acquisition will reallocate negotiating leverage across a set of component and consumables vendors; expect near-term margin pressure on smaller suppliers as Danaher extracts procurement efficiencies and bundles channels, while diagnostics and service players with complementary platforms could win cross-sell deals. Finally, integration execution risk for the acquirer is underappreciated by the market — even modest revenue synergies realized slowly will show up in margin profiles over 12–36 months, not immediately, creating a window to play relative-value trades between buyer and target.

Key Decisions for Investors

• Merger-arb small long MASI position sized 0.5–1.0% NAV: buy common up to a ~1–3% discount to deal-implied value where available, hedge with a short out-of-the-money call (1–2 strikes above deal level) to fund carry. Time horizon: 3–12 months. Risk/reward: limited upside (carry + small spread) vs tail loss (30–50% if deal breaks) — cap downside by sizing and option collar.
• Tail-risk asymmetric play: buy MASI Jan-2027 LEAP call spread (long ATM, short 25–35% OTM) sized 0.25–0.5% NAV to capture upside if deal fails or a competing bid emerges. Cost is low; payoff is large if litigation/regulatory reversal triggers re-opening of strategic auction.
• Relative-value: modest long DHR (1–2% NAV) on 12–24 month view — target strength from eventual synergy realization and cross-selling. Use a 6–12 month stop-loss at -12% to limit execution/integration risk. Reward: expect 8–15% IRR if mid-cycle synergies are achieved.
• Risk-off hedge: buy short-dated MASI puts (30–90 day) size 0.25% NAV to protect exposure into near-term legal/regulatory catalysts. These protect the merger-arb carry trade without materially reducing upside if deal completes.